Osimertinib monotherapy (EGFR-mut NSCLC, 1L metastatic OR adjuvant)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-OSIMERTINIB`

ID	`REG-OSIMERTINIB-NSCLC`
Type	Regimen
Status	pending_clinical_signoff
Diseases	None declared
Sources	`SRC-ESMO-NSCLC-METASTATIC-2024` `SRC-NCCN-NSCLC-2025`

Notes

FLAURA: superior PFS/OS vs 1G TKIs in 1L EGFR-mut metastatic. FLAURA2: osi + chemo extends PFS further. ADAURA: 3-year adjuvant in stage IB-IIIA EGFR-mut resected — 80% reduction in recurrence.

Used By

Handbook Chapters

HB-NSCLC-METASTATIC-1L - Metastatic NSCLC: driver-first treatment reasoning

Indication

IND-NSCLC-EGFR-MAINT-OSIMERTINIB - IND-NSCLC-EGFR-MAINT-OSIMERTINIB
IND-NSCLC-EGFR-MUT-MET-1L - IND-NSCLC-EGFR-MUT-MET-1L

Regimen

REG-AMI-LAZ-NSCLC - Amivantamab + Lazertinib (MARIPOSA) — 1L EGFR-mut NSCLC